Sildenafil improves renal function in patients with pulmonary arterial hypertension.

ABSTRACT:

Aim

Elevated serum creatinine (sCr) and low estimated glomerular filtration rate (eGFR) are associated with poor outcomes in patients with pulmonary arterial hypertension (PAH) whereas sildenafil treatment improves PAH outcomes. This post hoc analysis assessed the effect of sildenafil on kidney function and links with clinical outcomes including 6-min walk distance, functional class, time to clinical worsening and survival.

Methods

Patients with PAH received placebo or sildenafil 20, 40 or 80 mg three times daily in the SUPER-1 study and open-label sildenafil titrated to 80 mg three times daily (as tolerated) in the extension study.

Results

Baseline characteristics were similar among groups (n = 277). PAH was mostly idiopathic (63%) and functional class II (39%) or II

SUBMITTER: Webb DJ 

PROVIDER: S-EPMC4541971 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature